Evotec (OTCMKTS:EVTCY) Shares Pass Above 50 Day Moving Average - Should You Sell?

Key Points

• Evotec SE's stock (OTCMKTS:EVTCY) crossed above its 50-day moving average of $3.77 during trading, hitting a high of $3.77 before closing at $3.73.
• The company has a market cap of $1.23 billion and maintains a debt-to-equity ratio of 0.53, indicating a moderate financial leverage.
• Evotec specializes in drug discovery and development for pharmaceutical firms, offering both integrated and standalone solutions under their EVT Execute and EVT Innovate segments.

Evotec SE (OTCMKTS:EVTCY - Get Free Report)'s share price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $3.77 and traded as high as $3.77. Evotec shares last traded at $3.73, with a volume of 22,956 shares changing hands.

Evotec Stock Down 2.4%

The firm has a 50 day moving average price of $3.77 and a 200-day moving average price of $3.82. The company has a current ratio of 2.57, a quick ratio of 2.50 and a debt-to-equity ratio of 0.53. The firm has a market cap of $1.20 billion, a PE ratio of 8.88 and a beta of 0.98.

Evotec Company Profile

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties.